Last reviewed · How we verify
Micronutrient without zinc
Micronutrient without zinc is a Micronutrient supplement Small molecule drug developed by All India Institute of Medical Sciences. It is currently in Phase 3 development for Micronutrient deficiency correction, Nutritional support in clinical conditions requiring micronutrient supplementation (specific indication under phase 3 evaluation not publicly detailed). Also known as: study drug.
A micronutrient formulation that provides essential vitamins and minerals (excluding zinc) to correct nutritional deficiencies and support metabolic and physiological functions.
Micronutrients, excluding zinc, are studied in various conditions such as malnutrition, diabetes, inflammation, conjunctivitis, and stunting, with interventions including post-harvest fortified whole wheat flour flatbread. These micronutrients are small molecules that function as sunscreens or skin protectants, as indicated by their mechanism of action.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Micronutrient without zinc |
|---|---|
| Also known as | study drug |
| Sponsor | All India Institute of Medical Sciences |
| Drug class | Micronutrient supplement |
| Modality | Small molecule |
| Therapeutic area | Nutritional supplementation / Deficiency management |
| Phase | Phase 3 |
Mechanism of action
This is a supplemental micronutrient combination designed to address deficiencies in vitamins and minerals critical for immune function, wound healing, protein synthesis, and energy metabolism. By excluding zinc, the formulation may be tailored for specific patient populations or conditions where zinc restriction is clinically indicated, or to avoid interactions with concurrent zinc-containing therapies.
Approved indications
- Micronutrient deficiency correction
- Nutritional support in clinical conditions requiring micronutrient supplementation (specific indication under phase 3 evaluation not publicly detailed)
Common side effects
- Gastrointestinal upset
- Nausea
- Constipation or diarrhea
Key clinical trials
- Nutritional Intervention With Tenebrio Molitor Powder in Children With Chronic Malnutrition in the Democratic Republic of the Congo (NA)
- Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regulation (NA)
- Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese Safety (PHASE4)
- Prebiotic GOS and Lactoferrin With Iron Supplements (NA)
- Tralement vs. Fixed-dose Trace Element Combination Product in Patients >3 to 17 Years of Age Requiring Long-term PN (PHASE4)
- Efficacy of Zinc Fortified Fermented Wheat Flour (NA)
- Family-based Health Education Program and Zinc Supplementation for Stunted Mother (NA)
- Effects of EED on Zn Absorption and Retention in Children From a MNP (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Micronutrient without zinc CI brief — competitive landscape report
- Micronutrient without zinc updates RSS · CI watch RSS
- All India Institute of Medical Sciences portfolio CI
Frequently asked questions about Micronutrient without zinc
What is Micronutrient without zinc?
How does Micronutrient without zinc work?
What is Micronutrient without zinc used for?
Who makes Micronutrient without zinc?
Is Micronutrient without zinc also known as anything else?
What drug class is Micronutrient without zinc in?
What development phase is Micronutrient without zinc in?
What are the side effects of Micronutrient without zinc?
Related
- Drug class: All Micronutrient supplement drugs
- Manufacturer: All India Institute of Medical Sciences — full pipeline
- Therapeutic area: All drugs in Nutritional supplementation / Deficiency management
- Indication: Drugs for Micronutrient deficiency correction
- Indication: Drugs for Nutritional support in clinical conditions requiring micronutrient supplementation (specific indication under phase 3 evaluation not publicly detailed)
- Also known as: study drug
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing